{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:01:54Z","timestamp":1760731314979,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ensign Endowment for Gynecologic Cancer Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00404-020-05535-0","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T11:02:39Z","timestamp":1587121359000},"page":"1289-1298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Significance of lymph node ratio on survival of women with borderline ovarian tumors"],"prefix":"10.1007","volume":"301","author":[{"given":"David J.","family":"Nusbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel S.","family":"Mandelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8701","authenticated-orcid":false,"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"5535_CR1","first-page":"67","volume-title":"Surgery for ovarian cancer: Principles and practice, Chapt 3","author":"K Matsuo","year":"2015","unstructured":"Matsuo K, Sood AK, Gershenson DM (2015) Management of early-stage ovarian cancer. In: Bristow RE, Karlan BY (eds) Surgery for ovarian cancer: Principles and practice, Chapt 3, 3rd edn, vol 3. Informa Healthcare, New York, pp 67\u2013104","edition":"3"},{"key":"5535_CR2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.20080","volume":"100","author":"ME Sherman","year":"2004","unstructured":"Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100:1045\u20131052","journal-title":"Cancer"},{"key":"5535_CR3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00404-010-1539-5","volume":"283","author":"M Kanat-Pektas","year":"2011","unstructured":"Kanat-Pektas M, Ozat M, Gungor T, Sahin I, Yalcin H, Ozdal B (2011) Complete lymph node dissection: is it essential for the treatment of borderline epithelial ovarian tumors? Arch Gynecol Obstet 283:879\u2013884","journal-title":"Arch Gynecol Obstet"},{"key":"5535_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00404-007-0478-2","volume":"277","author":"ZM Pirimoglu","year":"2008","unstructured":"Pirimoglu ZM, Afsin Y, Guzelmeric K, Yilmaz M, Unal O, Turan MC (2008) Is it necessary to do retroperitoneal evaluation in borderline epithelial ovarian tumors? Arch Gynecol Obstet 277:411\u2013414","journal-title":"Arch Gynecol Obstet"},{"key":"5535_CR5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/annonc\/mdg173","volume":"14","author":"P Morice","year":"2003","unstructured":"Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P, Pomel C, Cot\u00e9 J-F, Haie-Meder C, Duvillard P (2003) Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 14:592\u2013598","journal-title":"Ann Oncol"},{"key":"5535_CR6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ygyno.2013.08.038","volume":"131","author":"T Guvenal","year":"2013","unstructured":"Guvenal T, Dursun P, Hasdemir PS, Hanhan M, Guven S, Yetimalar H, Goksedef BP, Sakarya DK, Doruk A, Terek MC, Saatli B, Guzin K, Corakci A, Deger E, Celik H, Cetin A, Ozsaran A, Ozbakkaloglu A, Kolusari A, Celik C, Keles R, Sagir FG, Dilek S, Uslu T, Dikmen Y, Altundag O, Ayhan A (2013) Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study. Gynecol Oncol 131:546\u2013550","journal-title":"Gynecol Oncol"},{"key":"5535_CR7","first-page":"671","volume":"100","author":"WE Winter III","year":"2002","unstructured":"Winter WE III, Kucera PR, Rodgers W, McBroom JW, Olsen C, Maxwell GL (2002) Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 100:671\u2013676","journal-title":"Obstet Gynecol"},{"issue":"438","key":"5535_CR8","first-page":"e1","volume":"204","author":"B Lesieur","year":"2011","unstructured":"Lesieur B, Kane A, Duvillard P, Gouy S, Pautier P, Lhomme C, Morice P, Uzan C (2011) Prognostic value of lymph node involvement in ovarian serous borderline tumors. Am J Obstet Gynecol 204(438):e1\u2013e7","journal-title":"Am J Obstet Gynecol"},{"key":"5535_CR9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/IGC.0000000000001154","volume":"28","author":"XQ Qian","year":"2018","unstructured":"Qian XQ, Hua XP, Wu JH, Shen YM, Cheng XD, Wan XY (2018) Clinical predictors of recurrence and prognostic value of lymph node involvement in the serous borderline ovarian tumor. Int J Gynecol Cancer 28:279\u2013284","journal-title":"Int J Gynecol Cancer"},{"key":"5535_CR10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ygyno.2006.05.022","volume":"103","author":"Y-H Cho","year":"2006","unstructured":"Cho Y-H, Kim D-Y, Kim J-H, Kim Y-M, Kim K-R, Kim Y-T, Nam J-H (2006) Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol 103:878\u2013882","journal-title":"Gynecol Oncol"},{"key":"5535_CR11","first-page":"5609","volume":"37","author":"K Gungorduk","year":"2017","unstructured":"Gungorduk K, Asicioglu O, Braicu EI, Almuheimid J, Gokulu SG, Cetinkaya N, Gungor T, Pakay G, Telli EU, Cuylan ZF (2017) The impact of surgical staging on the prognosis of mucinous borderline tumors of the ovaries: a multicenter study. Anticancer Res 37:5609\u20135616","journal-title":"Anticancer Res"},{"key":"5535_CR12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ygyno.2017.01.019","volume":"144","author":"K Matsuo","year":"2017","unstructured":"Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DM (2017) Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecol Oncol 144:496\u2013502","journal-title":"Gynecol Oncol"},{"key":"5535_CR13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1072-7515(02)01250-4","volume":"195","author":"S Camatte","year":"2002","unstructured":"Camatte S, Morice P, Atallah D, Pautier P, Lhomme C, Haie-Meder C, Duvillard P, Castaigne D (2002) Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg 195:332\u2013338","journal-title":"J Am Coll Surg"},{"key":"5535_CR14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.surg.2006.12.013","volume":"141","author":"TM Pawlik","year":"2007","unstructured":"Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, Choti MA (2007) Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141:610\u2013618","journal-title":"Surgery"},{"key":"5535_CR15","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s11605-009-0919-2","volume":"13","author":"H Riediger","year":"2009","unstructured":"Riediger H, Keck T, Wellner U, Zur Hausen A, Adam U, Hopt UT, Makowiec F (2009) The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 13:1337","journal-title":"J Gastrointest Surg"},{"key":"5535_CR16","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/SLA.0b013e318190eddc","volume":"248","author":"R Rosenberg","year":"2008","unstructured":"Rosenberg R, Friederichs J, Schuster T, Gertler R, Maak M, Becker K, Grebner A, Ulm K, H\u00f6fler H, Nekarda H (2008) Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3026 patients over a 25-year time period. Ann Surg 248:968\u2013978","journal-title":"Ann Surg"},{"key":"5535_CR17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/SLA.0b013e3181d7789d","volume":"251","author":"R Rosenberg","year":"2010","unstructured":"Rosenberg R, Engel J, Bruns C, Heitland W, Hermes N, Jauch K-W, Kopp R, P\u00fctterich E, Ruppert R, Schuster T (2010) The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann Surg 251:1070\u20131078","journal-title":"Ann Surg"},{"key":"5535_CR18","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1245\/s10434-012-2802-8","volume":"20","author":"DF Schneider","year":"2013","unstructured":"Schneider DF, Chen H, Sippel RS (2013) Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol 20:1906\u20131911","journal-title":"Ann Surg Oncol"},{"key":"5535_CR19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/ejso.2002.1239","volume":"28","author":"B Van der Wal","year":"2002","unstructured":"Van der Wal B, Butzelaar R, Van der Meij S, Boermeester M (2002) Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 28:481\u2013489","journal-title":"Eur J Surg Oncol"},{"key":"5535_CR20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.radonc.2003.10.015","volume":"70","author":"M Voordeckers","year":"2004","unstructured":"Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G (2004) The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 70:225\u2013230","journal-title":"Radiother Oncol"},{"key":"5535_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejso.2009.09.005","volume":"36","author":"Y Liu","year":"2010","unstructured":"Liu Y, Ma L, Wang S, Chen Y, Wu G, Han M, Wang X (2010) Prognostic value of lymph node metastases and lymph node ratio in esophageal squamous cell carcinoma. Eur J Surg Oncol 36:155\u2013159","journal-title":"Eur J Surg Oncol"},{"key":"5535_CR22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/bjs.1800810330","volume":"81","author":"J Roder","year":"1994","unstructured":"Roder J, Busch R, Stein H, Fink U, Siewert J (1994) Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 81:410\u2013413","journal-title":"Br J Surg"},{"key":"5535_CR23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.athoracsur.2012.01.065","volume":"93","author":"CE Nwogu","year":"2012","unstructured":"Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL, Miller A, Reid M (2012) Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg 93:1614\u20131620","journal-title":"Ann Thorac Surg"},{"key":"5535_CR24","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cncr.24290","volume":"115","author":"Y Xing","year":"2009","unstructured":"Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN (2009) Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115:2505\u20132513","journal-title":"Cancer"},{"key":"5535_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bjc.6603898","volume":"97","author":"J Chan","year":"2007","unstructured":"Chan J, Kapp D, Cheung M, Osann K, Shin J, Cohn D, Seid P (2007) The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 97:605\u2013611","journal-title":"Br J Cancer"},{"key":"5535_CR26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2014.11.010","volume":"136","author":"ND Fleming","year":"2015","unstructured":"Fleming ND, Frumovitz M, Schmeler KM, dos Reis R, Munsell MF, Eifel PJ, Soliman PT, Nick AM, Westin SN, Ramirez PT (2015) Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol 136:48\u201353","journal-title":"Gynecol Oncol"},{"key":"5535_CR27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2017.07.142","volume":"147","author":"S Polterauer","year":"2017","unstructured":"Polterauer S, Schwameis R, Grimm C, Macuks R, Iacoponi S, Zalewski K, Zapardiel I, Group VSC (2017) Prognostic value of lymph node ratio and number of positive inguinal nodes in patients with vulvar cancer. Gynecol Oncol 147:92\u201397","journal-title":"Gynecol Oncol"},{"key":"5535_CR28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ygyno.2019.02.007","volume":"153","author":"S Polterauer","year":"2019","unstructured":"Polterauer S, Schwameis R, Grimm C, Hillemanns P, Juckstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Furst ST, Strauss HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kolbl H, Reinthaller A, Woelber L, Mahner S (2019) Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: results from the AGO-CaRE-1 study. Gynecol Oncol 153:286\u2013291","journal-title":"Gynecol Oncol"},{"key":"5535_CR29","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.3802\/jgo.2018.29.e12","volume":"29","author":"A Ayhan","year":"2018","unstructured":"Ayhan A, Ozkan NT, Sari ME, Celik H, Dede M, Akbayir O, Gungorduk K, Sahin H, Haberal A, Gungor T, Arvas M, Meydanli MM (2018) Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study. J Gynecol Oncol 29:e12","journal-title":"J Gynecol Oncol"},{"key":"5535_CR30","doi-asserted-by":"crossref","first-page":"7952","DOI":"10.18632\/oncotarget.6911","volume":"7","author":"J Zhou","year":"2016","unstructured":"Zhou J, He ZY, Li FY, Sun JY, Lin HX, Wu SG, Chen QH (2016) Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study. Oncotarget 7:7952\u20137959","journal-title":"Oncotarget"},{"key":"5535_CR31","unstructured":"Overview of the SEER Program https:\/\/seer.cancer.gov\/about\/overview.html. Accessed 23 Apr 2019"},{"key":"5535_CR32","unstructured":"American Joint Committee on Cancer 3rd staging classification http:\/\/seer.cancer.gov\/seerstat\/variables\/seer\/ajcc-stage\/3rd.html. Accessed 14 May 2019"},{"key":"5535_CR33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2019.02.003","volume":"153","author":"K Matsuo","year":"2019","unstructured":"Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM (2019) Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: difference in characteristics and outcomes. Gynecol Oncol 153:230\u2013237","journal-title":"Gynecol Oncol"},{"key":"5535_CR34","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/AOG.0000000000003280","volume":"133","author":"K Matsuo","year":"2019","unstructured":"Matsuo K, Shimada M, Yamaguchi S, Matoda M, Nakanishi T, Kikkawa F, Ohmichi M, Okamoto A, Sugiyama T, Mikami M (2019) Association of radical hysterectomy surgical volume and survival of women with early-stage cervical cancer. Obstet Gynecol 133:1086\u20131098","journal-title":"Obstet Gynecol"},{"key":"5535_CR35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/CCO.0b013e32833b0dc1","volume":"22","author":"WG McCluggage","year":"2010","unstructured":"McCluggage WG (2010) The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol 22:462\u2013472","journal-title":"Curr Opin Oncol"},{"key":"5535_CR36","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.3802\/jgo.2018.29.e69","volume":"29","author":"K Matsuo","year":"2018","unstructured":"Matsuo K, Machida H, Mariani A, Mandelbaum RS, Glaser GE, Gostout BS, Roman LD, Wright JD (2018) Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer. J Gynecol Oncol 29:e69","journal-title":"J Gynecol Oncol"},{"key":"5535_CR37","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.6004\/jnccn.2016.0122","volume":"14","author":"RJ Morgan","year":"2016","unstructured":"Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen L-M, Copeland L, Crispens MA, DeRosa M, Dorigo O (2016) Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14:1134\u20131163","journal-title":"J Natl Compr Canc Netw"},{"key":"5535_CR38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ajog.2016.04.035","volume":"215","author":"SA Shazly","year":"2016","unstructured":"Shazly SA, Laughlin-Tommaso SK, Dowdy SC, Famuyide AO (2016) Staging for low malignant potential ovarian tumors: a global perspective. Am J Obstet Gynecol 215:153\u2013168e2","journal-title":"Am J Obstet Gynecol"},{"key":"5535_CR39","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.ejca.2013.01.035","volume":"49","author":"A du Bois","year":"2013","unstructured":"du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroder W, Munstedt K, Richter B, Kommoss S, Hauptmann S, Arbeitsgmeinschaft Gynakologische Onkologie Study G (2013) Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer 49:1905\u20131914","journal-title":"Eur J Cancer"},{"issue":"5","key":"5535_CR40","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00404-017-4496-4","volume":"296","author":"G Boyraz","year":"2017","unstructured":"Boyraz G, Salman MC, Gultekin M, Ozkan NT, Uckan HH, Gungorduk K, Gulseren V, Ayik H, Toptas T, Kuru O, Sozen H, Erturk A, Ozgul N, Meydanl\u0131 MM, Sanci M, Turan T, Gungor T, Simsek T, Topuz S, Yuce K (2017) What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case-control study. Arch Gynecol Obstet 296(5):979\u2013987","journal-title":"Arch Gynecol Obstet"},{"key":"5535_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0029-1186007","volume":"69","author":"A Du Bois","year":"2009","unstructured":"Du Bois A, Ewald-Riegler N, Du Bois O, Harter P (2009) Borderlinetumoren des Ovars\u2014eine systematische \u00dcbersicht. Borderline tumors of the ovary\u2014a systematic review. Geburtshilfe Frauenheilkd 69:1\u201327","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"5535_CR42","first-page":"10","volume-title":"WHO classification of tumours of female reproductive organs","author":"RJ Kurman","year":"2014","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumours of female reproductive organs, 4th edn. IARC International Agency for Research on Cancer, Lyon, pp 10\u201340","edition":"4"},{"issue":"1","key":"5535_CR43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2019.08.030","volume":"157","author":"K Matsuo","year":"2020","unstructured":"Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM (2020) Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecol Oncol 157(1):21\u201328","journal-title":"Gynecol Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05535-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-020-05535-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05535-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T15:49:45Z","timestamp":1666367385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-020-05535-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5535"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05535-0","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"type":"print","value":"0932-0067"},{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"assertion":[{"value":"18 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Consulting, Kiyatec and Merck; shareholder, Biopath; research funding, M-Trap (A.K.S.); honorarium, Chugai, textbook editorial, Springer, investigator meeting attendance expense, VBL therapeutics (K.M.); consultant, Quantagene (L.D.R.); Research funding, MSD (S.M.); stock and other ownership interests, Celgene, Johnson & Johnson, Biogin, consulting or advisory role, Clovis Oncology, research funding, Novartis, royalties from Elsevier as book editor, royalties from UpToDate for authorship (D.M.G.); none for others.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article used publicly available deidentified data and does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}